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Abstract
It is well known that cytokines are highly involved in the disease
process of rheumatoid arthritis (RA). Recently, targeting of
neuropeptides has been suggested to have potential
therapeutic effects in RA. The aim of this study was to
investigate possible interrelations between five neuropeptides
(bombesin/gastrin-releasing  peptide (BN/GRP), substance P
(SP), vasoactive intestinal peptide, calcitonin-gene-related
peptide, and neuropeptide Y) and the three cytokines tumour
necrosis factor (TNF)-α, IL-6, and monocyte chemoattractant
protein-1 in synovial fluid of patients with RA. We also
investigated possible interrelations between these
neuropeptides and soluble TNF receptor 1 in serum from RA
patients. Synovial fluid and sera were collected and assayed
with ELISA or RIA. The most interesting findings were
correlations between BN/GRP and SP and the cytokines. Thus,
in synovial fluid, the concentrations of BN/GRP and SP grouped
together with IL-6, and SP also grouped together with TNF-α
and monocyte chemoattractant protein-1. BN/GRP and SP
concentrations in synovial fluid also grouped together with the
erythrocyte sedimentation rate. In the sera, BN/GRP
concentrations and soluble TNF receptor 1 concentrations were
correlated. These results are of interest because blocking of SP
effects has long been discussed in relation to RA treatment and
because BN/GRP is known to have trophic and growth-
promoting effects and to play a role in inflammation and wound
healing. Furthermore, the observations strengthen a suggestion
that combination treatment with agents interfering with
neuropeptides and cytokines would be efficacious in the
treatment of RA. In conclusion, BN/GRP and SP are involved
together with cytokines in the neuroimmunomodulation that
occurs in the arthritic joint.
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Introduction
It has long been known that neuropeptides are secreted
locally during immune responses [1], and that they are
involved in vasodilation and plasma extravasation, that is,
neurogenic inflammation [2,3]. It is furthermore known that
inflammatory cells can produce neuropeptides [4,5]. The
neuropeptide substance P (SP) has been extensively exam-
ined in normal joints and in rheumatoid arthritis (RA) during
the past two decades. SP has known proinflammatory
properties, enhancing the proliferation of rheumatoid syn-
oviocytes [6] and inducing the release of the proinflamma-
tory mediator prostaglandin E2 and destructive enzymes
such as collagenase [6]. An increased level of SP has been
observed in the synovial fluid from RA patients [7-11].
Another neuropeptide is gastrin-releasing peptide (GRP)
[12], the mammalian homologue of bombesin (BN), a tetra-
decapeptide originally isolated from the skin of the frog
Bombina bombina [13]. BN/GRP-like peptides affect sev-
eral systems in mammals, such as satiety, thermal regula-
tion, nociception, and the activation of the sympatho-
adrenomedullary outflow [14,15]. We have recently shown
BN/GRP = bombesin/gastrin-releasing peptide; CGRP = calcitonin-gene-related peptide; ELISA = enzyme-linked immunosorbent assay; ESR = 
erythrocyte sedimentation rate; GRP = gastrin-releasing peptide; IL = interleukin; MCP-1 = monocyte chemoattractant protein-1; NPY = neuropep-
tide Y; RA = rheumatoid arthritis; RIA = radio-immunoassay; SP = substance P; sTNFR1 = soluble TNF receptor 1; Th = T helper (cells); TNF = 
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that BN/GRP-like peptides are present in joint fluid in arthri-
tis and that they are increased in amount in RA [11]. Sev-
eral other neuropeptides, such as vasoactive intestinal
peptide (VIP), calcitonin-gene-related peptide (CGRP),
and neuropeptide Y (NPY), have also been found in syno-
vial fluid from patients with RA [10,16]. VIP is a potent anti-
inflammatory agent [17,18]. It therefore has a beneficial
effect in collagen-induced arthritis (CIA) [17], inhibits the
production of proinflammatory factors, including tumour
necrosis factor (TNF)-α [19,20] and chemokines [21], and
inhibits IL-2 production in stimulated murine T lymphocytes
[22].
The proinflammatory cytokine TNF-α plays a central role in
the pathogenesis of RA [23,24]. Increased concentrations
of this cytokine in synovial fluid from RA patients have been
reported in several studies (e.g. [25-27]). It has also been
shown that TNF-α is expressed locally in joints of patients
with RA and in inflamed joints in experimentally induced
arthritis [28,29]. Increased concentrations of soluble TNF
receptors (sTNFRs) p55 (sTNFR1) and p75 (sTNFR2)
have been found in peripheral blood and synovial fluid from
patients with RA [30,31]. These receptors can bind TNF-α
and counteract its deleterious effects [30]. Serum concen-
trations of the two receptors have been correlated with RA
disease activity [32]. The proinflammatory cytokine IL-6 is
also found in elevated concentrations in the synovial fluid of
RA patients [33]. The chemokine monocyte chemoattract-
ant protein (MCP)-1 is a cytokine that attracts monocytes
to a site of inflammation [34,35]. This chemokine has been
suggested to be an important factor for the recruitment of
leukocytes to the joints in RA and is also found in elevated
concentrations in synovial fluid from RA patients [36-38].
Interactions between neuropeptides and cytokines are well
known (e.g. [39-41]), and it has been suggested that regu-
latory neuroimmune pathways in the joints are important
mechanisms modulating the expression of the arthritis [42].
However, there is limited information on the relations
between neuropeptides and cytokines in the synovial fluid
and serum from patients with RA. What is known is that SP
and IL-6 concentrations correlate in synovial fluid from
patients with RA [43]. Furthermore, the effect of SP on IL-
1, IL-6, and TNF-α production in RA was recently examined
[44]. CGRP has been found to reduce the production of IL-
6 and MMP-2 in RA synovial cells in vitro [18]. To the best
of our knowledge, there is no information at all on the
occurrence of a possible relation between BN/GRP and
cytokines in arthritic patients.
The lack of information on relations between neuropeptides
and cytokines in RA hampers the understanding of whether
neuropeptide-modifying agents, in addition to cytokine
antagonists such as TNF-α blockers, might be useful in the
treatment of RA. New information has led to suggestions
that treatments interfering with neuropeptides should be
tested in combination with pre-existing treatments [45]. A
number of neuropeptide receptor agonists and antagonists
produced during recent years have been found to have
effects in other situations [46-49]. Actually, using an animal
model of RA, collagen-induced arthritis, it was shown that
VIP affected the Th1/Th2 balance by inhibiting the synthe-
sis of Th1 cytokines and inducing the synthesis of Th2
cytokines [17]. Also, the results of recent studies in vitro on
cells of human origin have suggested that modulation of the
effects of neuropeptides may be a new strategy for the
treatment of arthritis [50,51]. In the present study, we
therefore aimed to investigate the relation between the con-
centrations of three cytokines (TNFα, IL-6, and MCP-1) and
several neuropeptides (BN/GRP, SP, NPY, VIP, and
CGRP) in the synovial fluid from patients with RA, stratified
for early and long-standing disease. We also studied the
concentrations of sTNFR1 in relation to these neuropep-
tides in serum. We found that BN/GRP and SP showed
correlations with the proinflammatory cytokines in the
group with long-standing RA.
Materials and methods
Patients and material
Thirty-five consecutive patients (25 women and 10 men)
with RA according to the criteria of the American Rheuma-
tism Association [52], having active inflammation of the
knee joints, were included in the study. The patients were
divided into two groups, depending on their disease dura-
tion. Patients were defined as having 'early RA' (n = 7;
mean age, 51 years) or 'long-standing RA' (n = 23 to 28;
mean age, 59 years). Median time when sampling of blood
and synovial fluid for the early RA group was 8.0 months
from onset of symptoms (interquartile range = 5.6 months);
the median duration from onset of symptoms until diagno-
sis was 6.0 months. The early RA group were thus those
patients who had had RA for less than approximately 12
months, and the patients in the long-standing RA group
were those patients whose disease had lasted for more
than a year.
The synovial fluid was aspirated according to the method of
Dixon and Emery [53]. The aspirates were centrifuged, and
the leukocytes were removed. The samples were frozen
and stored at -80°C until assay. Blood samples were also
collected concurrently from patients whose synovial fluid
was examined: patients with early RA (n = 4) or with long-
standing RA (n = 22). The sera were frozen and stored at -
80°C until assay. The erythrocyte sedimentation rate (ESR)
was measured for all the patients.
Synovial fluid (n = 2 to10) and serum (n = 2 to 11) was also
obtained from healthy controls (mean age, 39 years). The
samples were collected, frozen, and stored in the same way
as the material from the RA patients.Available online http://arthritis-research.com/content/7/3/R416
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The study protocol was approved by the Ethical Committee
at the Faculty of Medicine, Umeå University, and the exper-
iments were conducted according to the principles
expressed in the Declaration of Helsinki.
Enzyme-linked immunosorbent assay/enzyme 
immunoassay
The concentration of TNF-α in joint fluid was determined
using a Human ELISA TNFα kit (Pierce-Endogen, Rock-
ford, IL, USA) in accordance with the instructions from the
manufacturer. The detection limit in this particular assay
was cited as 2 pg/ml. The receptor level of sTNFR1 in
serum was measured using a Human Quantikine sTNF R1
kit (R&D Systems, Wiesbaden-Nordenstadt, Germany).
The minimum detectable level for this assay was 0.77 pg/
ml. The concentrations of MCP-1 and IL-6 were determined
with Human ELISA kits (Pierce-Endogen). The minimum
detectable concentrations for these assays were <10 pg/
ml and <1 pg/ml, respectively. The concentrations of the
neuropeptides BN/GRP and SP (in serum) and of the neu-
ropeptides CGRP, NPY, and VIP (in joint fluid and serum)
were measured using Enzyme Immunoassay kits (Phoenix
Pharmaceuticals, Belmont, CA, USA) in accordance with
the supplier's assay instructions. The detection limits for
the neuropeptides were as follows: BN/GRP, 300 pg/ml;
CGRP, 230 pg/ml; NPY, 130 pg/ml; SP, 90 pg/ml; and
VIP, 80 pg/ml.
Radio-immunoassay
For determining concentrations of BN/GRP and SP in joint
fluid, RIAs were performed. These conform to the analyses
described and presented in a previous study [11]. The con-
centrations of BN/GRP-like material in joint fluid were
determined using a 125I-RIA kit (Peninsula Laboratories Inc,
San Carlos, CA, USA) in accordance with the manufac-
turer's instructions. The detection limit in this particular
assay was cited as 10 pg/ml. For the SP assay, a 125I-RIA
kit (Eurodiagnostica, Malmö, Sweden) was employed. The
sensitivity of the assay was 2.5 pg/ml.
Statistics
Differences between the continuous data for concentra-
tions of the investigated substances in the two subject
groups (early RA, long-standing RA) were analysed using
the Mann–Whitney U test. Correlation analyses were per-
formed with the Spearman rank correlation test. P values
<0.05 were considered significant. Because the amounts
of synovial fluid and serum from healthy controls varied, no
statistical analysis was performed in this case.
Factor analysis, that is, explorative data analysis, was also
performed to find patterns among the measured variables.
In this case, because of the number of samples available,
the pattern for long-standing RA was evaluated. Factor
loadings >0.3 were considered. The factor analyses were
performed by SPSS with Varimax, with Kaiser normalisation
as a rotation method. For the statistical calculations, values
below the detection limit were set to 50% of the detection
limit and values beyond the highest standard point were set
to the highest linearly detectable concentration.
Results
Cytokines in synovial fluid
Concentrations of immunoreactive TNF-α in synovial fluid
were detected in most of the patients (approximately 70%).
Table 1 shows medians and interquartile ranges of the con-
centrations found. No significant differences were found
between the two disease groups (Mann–Whitney test).
The concentrations of immunoreactive IL-6 in synovial fluid
were detected in 95% of the patients with RA. Medians
and interquartile ranges are shown in Table 1. The patients
with early RA had significantly higher concentrations of IL-
6 than the other group (P < 0.05) (Fig. 1a). The chemoat-
tractant cytokine MCP-1 was detected in all patients, (see
Table 1). No significant differences were found between
the two groups for MCP-1. Values found for control
patients are shown in Table 1.
Neuropeptides in synovial fluid
The neuropeptides BN/GRP, CGRP, NPY, SP, and VIP
were detected in synovial fluid in 70 to 95% of the patients
(Table 1). A statistically significant difference between the
two groups, patients with early and those with long-stand-
ing RA, was found only for BN/GRP (P < 0.05) (Fig. 1b).
SP and BN/GRP values in healthy controls were signifi-
cantly lower than in the two disease groups (P < 0.001)
(Fig. 1b,c). The values found for control patients are shown
in Table 1.
sTNFR1 in serum
Soluble TNFR1 was measurable in sera from all subjects
(Table 2; Fig 2a.) Differences between the two disease
groups were close to significance (P < 0.09).
Neuropeptides in serum
The concentrations of the neuropeptides BN/GRP, CGRP,
NPY, SP, and VIP in sera were measurable in 85 to 100%
of the patients (Table 2). Statistically significant differences
between the two groups of patients, those with early and
those with long-standing RA, were found for BN/GRP (P <
0.05) (Fig. 2b) and for SP (P < 0.05). The values found for
control patients are shown in Table 2.
Correlations between cytokines and neuropeptides in 
synovial fluid
Spearman rank correlations between the concentrations of
cytokines and those of the five neuropeptides were calcu-
lated. There was a correlation between IL-6 and BN/GRP-
like peptides in long-standing RA but not in early RA (Fig.Arthritis Research & Therapy    Vol 7 No 3    Grimsholm et al.
R419
3). There was also a correlation between TNF-α and BN/
GRP-like peptides in long-standing RA (rs = 0.40; P  <
0.05), but not in the early RA group.
Factor analysis performed on the long-standing RA group
yielded four factors with eigenvalues >1, explaining 78% of
the total variation between the measured variables (Table
3). SP, BN/GRP, and IL-6 grouped together, with the larger
loadings on BN/GRP and on IL-6 (Table 3) in the group
with long-standing RA. There was also an interrelation
between SP, TNF-α, and MCP-1. None of the other three
neuropeptides (NPY, CGRP, and VIP) showed any correla-
tion with any of the cytokines. The ESR grouped together
with three neuropeptides (BN/GRP, SP, and CGRP), with
the largest loadings on SP and on the ESR.
Figure 1
Box–whisker plots showing concentrations in synovial fluid for rheumatoid arthritis and healthy controls Box-whisker plots showing concentrations in synovial fluid for rheumatoid arthritis and healthy controls. (a) IL-6; (b) bombesin/gastrin-releasing pep-
tide; (c) substance P. Boxes show the 25th and 75th percentiles; horizontal lines in boxes show the medians; whiskers show the 10th and 90th per-
centiles. *P < 0.05.
Figure 2
Box–whisker plots showing concentrations in serum for the patients with rheumatoid arthritis and healthy controls Box–whisker plots showing concentrations in serum for the patients with rheumatoid arthritis and healthy controls. (a) Soluble tumour necrosis fac-
tor receptor 1; (b) bombesin/gastrin-releasing peptide. Boxes show the 25th and 75th percentiles; horizontal lines in boxes show the medians; 
whiskers show the 10th and 90th percentiles. *P < 0.05.Available online http://arthritis-research.com/content/7/3/R416
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Correlations between sTNFR1 and neuropeptides in 
serum
Strong correlations on the Spearman rank test (rs = 0.61; P
< 0.05) between concentrations of BN/GRP and those of
sTNFR1 were found in the group with long-standing RA,
but not in that with early RA (Fig. 4). No correlations were
found between sTNFR1 concentrations and the concentra-
tions of the other neuropeptides.
Factor analysis performed on the group with long-standing
RA yielded three factors with eigenvalues >1, explaining
81% of the total variation between the measured variables
(Table 4). It can be seen here that BN/GRP grouped
together with sTNFR1 and CGRP. None of the other
neuropeptides showed any correlation with sTNFR1. It was
also seen that the ESR grouped together with sTNFR1.
Correlations between the neuropeptides in synovial fluid
Spearman rank correlations showed that the concentra-
tions of NPY in synovial fluid correlated with those of SP (rs
= 0.41; P < 0.05), VIP (rs = 0.69; P < 0.01), and CGRP (rs
= 0.52; P < 0.05). VIP also correlated with CGRP (rs = 0.7;
P < 0.001).
Factor analysis showed that all five neuropeptides grouped
together, with the larger loadings on VIP, CGRP, and NPY
(Table 3).
Correlations between the neuropeptides in serum
Spearman's rank correlations showed that the concentra-
tions of BN/GRP in serum correlated with those of CGRP
(P < 0.01; r = 0.70), VIP (P < 0.05; r = 0.51), and SP (P <
0.01; r = 0.58). Concentrations of SP also correlated with
those of CGRP (P < 0.01; r = 0.54) and VIP (P < 0.001; r
= 0.83). Furthermore, the concentrations of VIP correlated
with the those of CGRP (P < 0.01; r = 0.54).
All the neuropeptides grouped together in the factor analy-
sis on serum (Table 4).
Discussion
In the present study, the relations between various neu-
ropeptides and cytokines in joint fluid and serum of RA
Table 1
Cytokine and neuropeptide concentrations in synovial fluid
Substance Early RA (pg/ml) Long-standing RA (pg/ml) P Controls (pg/ml)
Cytokine
TNF-α 8.0a 7.0c ns nm
(1.0–47) (1.0–24)
IL-6 5100b 3100d <0.05 ndf
(4500–8000) (1300–3900)
MCP-1 1200b 1500d ns 620f
(810–1800) (1200–3000)
Neuropeptide
BN/GRP 31a 17c <0.05 ndg
(21–39) (7.0–23)
CGRP 580b 450d ns ndf
(160–1500) (230–960)
NPY 190b 260e ns 180f
(65–320) (170–500)
SP 48a 58c ns ndg
(36–80) (42–77)
VIP 150b 300d ns nm
(40–200) (55–630)
Concentrations were measured by ELISA and RIA in synovial fluid from the knee joints of patients with RA and in healthy control subjects. Values 
are medians (and Q1–Q3). P relates to long-standing RA versus early RA (Mann–Whitney test). an = 7; bn = 6; cn = 28; dn = 23; en = 25; fn = 2; 
gn = 10. BN/GRP, bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; MCP-1, monocyte chemoattractant protein-1; nd, 
not detectable; nm, not measured; NPY, neuropeptide Y; ns, not significant; RA, rheumatoid arthritis; SP, substance P; TNF, tumour necrosis 
factor; VIP, vasoactive intestinal peptide.Arthritis Research & Therapy    Vol 7 No 3    Grimsholm et al.
R421
patients were examined. Although there were, to a certain
extent, correlations between the various neuropeptides
examined, a major finding was that BN/GRP and SP were
the neuropeptides that correlated most clearly with the
cytokines, with BN/GRP showing the highest degree of
correlation. We stress that the occurrence of possible rela-
tions were sought extensively, using both Spearman corre-
lation analyses and factor analysis. We also observed that
the concentrations of BN/GRP and SP in synovial fluid
grouped together with the ESR. These observations sug-
gest that BN/GRP and SP are connected to inflammation
in the joint. Comparison with the values obtained from
healthy controls showed clearly that in the patients in the
long-standing RA group, there were increases in concen-
trations of the cytokines examined, as well as in concentra-
tions of SP and BN/GRP. It is well established that TNF-α
is undetectable in synovial fluid from healthy controls
[23,27].
CGRP, NPY, SP, and VIP have all been shown to affect
cytokine production/release from various immune cells
[39,40,44,54]. For example, SP can modulate the release
of IL-1, IL-6, and TNF-α from human blood monocytes [39].
The stimulatory effect of SP on these proinflammatory
cytokines was due to an augmented secretion from the
immunocompetent cells [41]. SP and VIP have opposite
roles concerning the regulation of TNF-α production, VIP
inhibiting the production of TNF-α from, for example, micro-
glia, and SP increasing the TNF-α production from mast
cells and other types of inflammatory cells [40,41]. The
impact of neuropeptides on cytokine production and
release in RA is not well known. However, in a recent study
it was shown that CGRP, NPY, SP and VIP could affect the
IL-1β, TNF-α, and IL-6 production by peripheral whole
blood cells from RA patients [44]. In the present study, we
searched for possible correlations of TNFα, IL-6, and MCP-
1 with all neuropeptides included in the analyses of the syn-
ovial fluid, but no correlations were found concerning VIP,
NPY, or CGRP. The situation was the same for correlation
matrices between sTNFR1 and these three neuropeptides
in serum.
Because IL-6 was found in elevated concentrations in the
synovial fluid of RA patients [33,55], the importance of this
cytokine in RA and other diseases has been thoroughly
investigated. It has been shown that IL-6 regulates acute-
phase proteins such as C-reactive protein and haptoglobin
[33,55]. Furthermore, a humanised anti-IL-6 receptor anti-
body has been found to inhibit IL-6 significantly and to
improve the signs and symptoms of RA [56]. In the analysis
of synovial fluid in the present study, we found that BN/
GRP and SP grouped together with IL-6, with the strongest
loadings on BN/GRP and on IL-6. This is one of the major
findings leading to the interpretation that these two neu-
ropeptides correlate more closely than the others with dis-
ease activity in RA. In the synovial fluid of patients with long-
standing RA, there was also a correlation between BN/
GRP and TNF-α. As it is well known that TNF-α and other
cytokines may occur in insufficient concentrations in serum
(e.g. [57]), we analysed sTNFR1 in serum and found that
the receptor concentrations correlated with concentrations
of BN/GRP on the Spearman's rank analysis and that they
grouped together on the factor analysis.
Figure 3
Scatter plot, with linear regression line, showing correlation between  BN/GRP and IL-6 in synovial fluid Scatter plot, with linear regression line, showing correlation between 
BN/GRP and IL-6 in synovial fluid. Spearman's rank correlation coeffi-
cient (rs = 0.38; P < 0.05) measured, using RIA and ELISA, in synovial 
fluid from patients with long-standing RA. BN/GRP, bombesin/gastrin-
releasing peptide; RA, rheumatoid arthritis.
Figure 4
Scatter plot, with linear regression line, showing correlation between  BN/GRP and sTNFR1 in serum Scatter plot, with linear regression line, showing correlation between 
BN/GRP and sTNFR1 in serum. Spearman's rank correlation coeffi-
cient (rs = 0.61; P < 0.05), measured, using ELISA, in serum from 
patients with long-standing RA. BN/GRP, bombesin/gastrin-releasing 
peptide; RA, rheumatoid arthritis; sTNFR1, soluble TNF receptor 1.Available online http://arthritis-research.com/content/7/3/R416
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It has long been discussed as to whether SP is clinically
significant in RA, and accordingly whether SP-receptor
antagonists block joint inflammation (e.g. [58,59]). In early
studies, it was shown that intra-articular injections of SP
increased the severity of the arthritis [60]. This substance
was also early shown to facilitate the production and
release of proinflammatory mediators such as prostaglan-
din E2 and destructive enzymes such as collagenase [6]. In
more recent studies, intra-articular injection of SP was
found to lead to endothelial-cell proliferation [61]. The over-
Table 2
Concentrations of sTNFR1 and neuropeptides in serum
Variable Early RA (pg/ml) Long-standing RA (pg/ml) P Controls (pg/ml)
sTNFR1 1500a 1900b ns 1200d
(1300–1700) (1600–2000)
BN/GRP 3000a 1700b <0.05 340e
(2400–3300) (430–2500)
CGRP 1500a 820b ns 310e
(1100–1600) (510–1600)
NPY 610a 900c ns 930f
(370–890) (700–1900)
SP 170a 410b <0.05 180g
(150–300) (320–440)
VIP 250a 280b ns 290g
(210–280) (230–340)
ESR 20a 32b ns nm
(7 – 32) (22 – 47)
Concentrations were measured using ELISA. Values are medians (and Q1–Q3). The ESR is also shown. P relates to long-standing RA versus 
early RA. an = 4; bn = 22; cn = 21; dsTNFR1 value in healthy controls according to the manufacturer; en = 4; fn = 2; gn = 11. BN/GRP, bombesin/
gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; ESR, erythrocyte sedimentation rate; NPY, neuropeptide Y; nm, not measured; 
ns, not significant; RA, rheumatoid arthritis; SP, substance P; sTNFR1, soluble tumour necrosis factor receptor 1; VIP, vasoactive intestinal 
peptide.
Table 3
Factor analysis on cytokines and neuropeptides in synovial fluid
Variable Factor
1234
TNF-α 0.751
IL-6 0.913
MCP-1 0.912
BN/GRP -0.436 0.623 0.327
SP 0.409 0.33 0.361 0.671
VIP 0.784
CGRP 0.715 -0.472
NPY 0.893
ESR 0.71
Principal-component analysis for cytokines and neuropeptides in synovial fluid from 23 patients with long-standing RA, and for the ESR. BN/GRP, 
bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; ESR, erythrocyte sedimentation rate; MCP, monocyte 
chemoattractant protein-1; NPY, neuropeptide Y; RA, rheumatoid arthritis; SP, substance P; TNF, tumour necrosis factor; VIP, vasoactive 
intestinal peptide.Arthritis Research & Therapy    Vol 7 No 3    Grimsholm et al.
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all role of SP in RA has recently been extensively discussed
and it was concluded that the therapeutic potential of SP
receptor (neurokinin-1 receptor) antagonists should not be
ignored [45].
SP is present in the nerve fibres of the synovium [62]. How-
ever, both up- [63] and down- [64] regulation of SP expres-
sion has been noted for arthritic joints. In accord with these
observations, up- and down-regulations of neuropeptide
expressions occur in relation to the activity of inflammatory
disease in other tissues [65,66]. A reason for decreased
magnitude of SP in the nerve fibres of joint capsules may
be the occurrence of a local release of SP, leading to a
depletion of SP-containing nerve fibres [67-69]. There are
also diverging observations concerning the occurrence of
increases or decreases of SP concentrations in the syno-
vial fluid of arthritic patients (cf. [7,10,11,16,70-72]). Tak-
ing into consideration that neuropeptide and cytokine
concentrations may vary depending upon the stage of
arthritis for the patients examined and that differences in
actual neuropeptide concentrations in serum between dif-
ferent patients should be interpreted with caution, an
advantage of the present study is that it focuses on
intraindividual comparisons of neuropeptide and cytokine
concentrations.
It is not clear whether BN/GRP-like peptides are present in
joint innervation, or how the release of the peptides into the
synovial fluid occurs. An interesting observation is that BN/
GRP-like peptides have been detected in human chondro-
cytes [73]. In any case, BN/GRP-like peptides are well
known to have trophic and growth-promoting effects in var-
ious parts of the body. Thus, these peptides have paracrine
and autocrine trophic effects in certain cancers, such as
small-cell lung cancer and colon cancer [74-76], and are
likely to have trophic effects on the salivary glands after irra-
diation [77] and to promote proliferation of fetal chondro-
cytes [78]. Furthermore, GRP receptors have
morphogenetic properties for colon cancer cells, these
being mediated via focal adhesion kinase [79]. The expres-
sion of BN/GRP-like peptides in the spinal cord is influ-
enced by glucocorticoids [80], which may be of interest for
the understanding of the effects of treatments of RA
patients, many of whom are treated with glucocorticoids.
Concerning inflammation, it has been shown that BN/GRP-
like peptides ameliorate burn-induced intestinal inflamma-
tion by preventing the sequestration of neutrophils in the
injured tissue [81] and that these peptides presumably are
mediators of inflammatory reactions during pulmonary
inflammation [82]. Furthermore, BN ameliorates colonic
damage in experimental colitis [83], which suggests that
the peptide may be involved in restoring intestinal damage
in inflammatory bowel disease. Treatment with BN/GRP
has also been found to have antiulcerogenic and anti-
inflammatory actions, related to effects on chronic gastric
ulcers and burn-induced and colitis-induced gut injury [84].
Furthermore, topical use of GRP has been found to pro-
mote cutaneous wound healing [85].
The present study is relevant because neuropeptides have
been suggested to be efficacious antiarthritic drugs
[17,50,51]. Thus, VIP was shown to be effective as an anti-
inflammatory agent in vivo for collagen-induced arthritic
mice [17,86]. Furthermore, a recent study on human cells
in vitro showed that VIP can down-regulate the expression
and synthesis of chemokines in synovial tissue cells and
fibroblast-like synoviocytes from RA patients and that VIP
inhibits the production of TNF-α after TNF-α stimulation
[51]. The results obtained by Foey and collaborators [50]
show that the studied neuropeptide (VIP) is not on its own
a useful therapeutic agent in the treatment of RA but may
be useful in combination with phosphodiesterase inhibitor.
In line with this idea, it has frequently been suggested that
various types of combination treatments might be effective
Table 4
Factor analysis on sTNFR1 and neuropeptides in serum
Variable Factor
123
sTNFR1 0.323 0.827
BN/GRP 0.324 0.778
SP 0.907
VIP 0.934
CGRP 0.63 0.575
NPY 0.925
ESR 0.897
Principal-component analysis for sTNFR1 and five neuropeptides in serum from 21 patients with long-standing RA, and for the ESR. BN/GRP, 
bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; ESR, erythrocyte sedimentation rate; NPY, neuropeptide Y; RA, 
rheumatoid arthritis; SP, substance P; sTNFR1, soluble tumour necrosis factor receptor 1; VIP, vasoactive intestinal peptide.Available online http://arthritis-research.com/content/7/3/R416
R424
in diseases such as RA. It was initially suggested that a
combination therapy targeting two cytokines instead of one
would be the treatment of choice for RA [87] and other
autoimmune diseases [88]. However, in a recent clinical
trial it was observed that a combination therapy with a
recombinant IL-1 receptor antagonist and polyethylene-gly-
col-conjugated sTNFRI (etanercept) did not result in an
improvement of the clinical factors of RA in comparison
with etanercept alone [89]. Alternative combination treat-
ments might in the future include treatments targeting
cytokine and neuropeptide. In line with this idea, it was
recently suggested that SP-receptor (neurokinin-1 recep-
tor) antagonists might be useful in combination with pre-
existing treatments in RA [45]. In a recent study, a combi-
nation of common chemotherapy and immunotherapy tar-
geting BN/GRP-receptor with a synthetic BN/GRP
antagonist was found to enhance the killing of small-cell
lung cancer cells [90].
As discussed above, there is indeed evidence showing that
neuropeptides can modify the secretion of proinflammatory
cytokines from immunocompetent cells. That includes the
situation for peripheral blood cells from patients with RA
[44]. As seen in the present study, BN/GRP and SP are the
peptides that show correlations with the inflammatory
cytokines in RA. Thus, we tentatively suggest that the
increased concentrations of BN/GRP and SP may stimu-
late cytokine production from immunocompetent cells in
RA. The findings that neurokinin-1 receptor is not only
detectable on immunocompetent cells, but also on rheuma-
toid synoviocytes [91] and on endothelial cells in synovitis
[61], strengthen the suggestion that SP plays an important
role in the rheumatoid joint. In future studies, it would there-
fore be of interest to investigate whether BN/GRP and its
receptor are active during the rheumatic process, and
whether treatments interfering with the effects of BN/GRP
or SP or both, possibly in parallel with medications affect-
ing cytokine effects, are of value in RA.
Conclusion
The neuropeptides that showed correlations with the proin-
flammatory cytokines in the patient material examined were
BN/GRP and SP, particularly BN/GRP. The observations
give new insight into further studies of neuropeptide/
cytokine interrelations in RA.
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